Archive for the ‘duplication retractions’ Category
A journal has retracted a paper by a leading diabetes researcher — who has also issued three corrections — after questions about her research were raised on PubPeer.
The ongoing comments have led Maedler to carefully look through her original data, according to a statement she emailed us: Read the rest of this entry »
The paper — about an “extremely rare” instance where a fetus was diagnosed with both a form of dwarfism and a chromosomal condition known as Klinefelter syndrome — was retracted from Case Reports in Obstetrics and Gynecology (CROG).
The first author of the paper told us the report was the result of a “big misunderstanding” between her and a former colleague, and she alerted the journal as soon as she noticed the case had already been reported in BMC Pediatrics.
A small survey of UK academics suggests misconduct such as faking data and plagiarism is occurring surprisingly often.
The survey — of 215 UK academics — estimated that 1 in 7 had plagiarized from someone else’s work, and nearly 1 in 5 had fabricated data. Here’s how Joanna Williams and David Roberts at the University of Kent summarize the results in their full report, published by the Society for Research into Higher Education: Read the rest of this entry »
A bone researcher in Japan has logged his sixth retraction, after acknowledging he duplicated substantial portions of a 2011 paper and added “honorary” co-authors.
The retraction, in Parkinsonism & Related Disorders, follows five others for Yoshihiro Sato, including one from JAMA, some of which were pulled over concerns regarding authorship and data integrity. The latest retraction duplicated text from another 2005 paper that was itself retracted last year, both for duplicating from this newly retracted paper and for “concerns about the underlying data.”
Sato — who is listed at Mitate Hospital on the paper — told the journal he takes full responsibility.
According to the notice issued by the American Journal of Physiology – Renal Physiology (AJP), the last author initiated the investigation at the University of Houston in Texas, which found the first author — Mousa Abkhezr — to be guilty of falsifying and duplicating images.
We’ve obtained a copy of the investigation report, which concluded that Abkhezr committed misconduct “recklessly,” and the paper must be retracted. Although the report noted that Abkhezr argued that the problems stemmed from an honest error, the investigation committee ruled that data from the retracted paper cannot be included in his doctoral thesis.
The last author told us there is a separate ongoing “academic honesty enquiry” into Abkhezr’s dissertation.
One journal has retracted a paper containing images that recently raised suspicions of obvious duplications, and another journal is planning to do the same.
Scientists first leveled accusations against the newly retracted paper in Scientific Reports, along with two others by the same researchers, earlier this month on Twitter. One other journal — PeerJ — has announced that it plans to retract one of the questioned papers, as well. The third paper, in Frontiers in Pharmacology, bears an expression of concern.
It was unusually quick action on the part of the journals, as well as the authors’ host institution, the University of Malaya, which announced last week the authors had manipulated figures in all three papers, along with one other.
Here’s today’s retraction notice from Scientific Reports for “Novel piperazine core compound induces death in human liver cancer cells: possible pharmacological properties:”
Bharat Aggarwal, a highly cited cancer researcher who retired last year from MD Anderson, has logged two retractions following an investigation into his work, bringing his total to nine.
Aggarwal has threatened to sue us in the past, and told us that MD Anderson has been investigating his work. Earlier this year, Biochemical Pharmacology retracted seven studies of which he is the only common author, noting the “data integrity has become questionable.” Now, he’s earned two more retractions in Molecular Pharmacology, both for “inappropriate” or “unacceptable” image manipulation.
Both of the notices are paywalled (tsk, tsk). Here’s one for “Flavopiridol suppresses tumor necrosis factor-induced activation of activator protein-1, c-Jun N-terminal kinase, p38 mitogen-activated protein kinase (MAPK), p44/p42 MAPK, and Akt, inhibits expression of antiapoptotic gene products, and enhances apoptosis through cytochrome c release and caspase activation in human myeloid cells:” Read the rest of this entry »
The Leiden University Medical Center (LUMC) has asked a journal to retract two papers after revealing a former employee manipulated data.
The report does not name the individual nor the journal, but notes that they work in a molecular field, and are currently employed by a university outside The Netherlands.
Many figures in four papers by a research team in Malaysia contain duplication or manipulation, a university committee has found, calling for multiple retractions.
We learned about issues with three of the papers, including one in Scientific Reports, earlier this week when they were the talk of Twitter. As journals issued expressions of concern, and an expert wondered how the papers passed peer review at all, the first author, a researcher at the University of Malaya (UM), denied allegations of duplication.
UM was alerted to allegations of misconduct in the Scientific Reports paper last Saturday, and according to a statement published today:
Last week, users alleged on Twitter that three papers by the same team included pictures of cells that were copied and pasted. First author Nima Samie, affiliated with University of Malaya in Malaysia, denied the accusations — but both the Malaysian government and now two journals sees cause for further investigation.
Frontiers in Pharmacology published an expression of concern this morning: